Flash FinanceUS
Market closed S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Knowles (KN)

Knowles appoints Laura Angelini, former Baxter executive, to its board of directors

Neutral Impact 2 of 5 leadership Written later

Knowles Corporation's Board elected Laura Angelini as a new director on December 6, 2024, and appointed her to the Compensation Committee. The Board determined she is independent under New York Stock Exchange listing standards, and the company announced the appointment in a press release on December 9, 2024.

Key points

  • Laura Angelini was elected to the Board on December 6, 2024, and will serve until the next annual shareholder meeting.
  • Ms. Angelini has 30 years of medical device and healthcare experience, including General Manager of the Renal Care Global Business Unit at Baxter International from 2016 to 2021.
  • Non-employee director pay has generally included a $235,000 annual retainer and a one-time grant of $170,000 in restricted stock units, with prorated amounts for her first year.
  • The Board has determined Ms. Angelini meets the company's independence standards and NYSE listing standards.

The filing

CompanyKnowles (KN)
Form8-K, current report
Filed with the SECDec 9, 2024, 12:25 PM ET
Accession number0001587523-24-000096

Items reported: 5.02 Director / Officer Change7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:49 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on December 09, 2024.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.